- Home
- ATNI vs VOR Comparison
ATNI vs VOR Comparison
Compare ATNI & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNI
- VOR
- Stock Information
- Founded
- ATNI 1987
- VOR 2015
- Country
- ATNI United States
- VOR United States
- Employees
- ATNI N/A
- VOR N/A
- Industry
- ATNI Telecommunications Equipment
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- ATNI Telecommunications
- VOR Health Care
- Exchange
- ATNI Nasdaq
- VOR Nasdaq
- Market Cap
- ATNI 226.4M
- VOR 207.1M
- IPO Year
- ATNI 1991
- VOR 2021
- Fundamental
- Price
- ATNI $19.84
- VOR $9.86
- Analyst Decision
- ATNI
- VOR Buy
- Analyst Count
- ATNI 0
- VOR 6
- Target Price
- ATNI N/A
- VOR $84.00
- AVG Volume (30 Days)
- ATNI 44.1K
- VOR 826.5K
- Earning Date
- ATNI 11-05-2025
- VOR 11-07-2025
- Dividend Yield
- ATNI 5.59%
- VOR N/A
- EPS Growth
- ATNI N/A
- VOR N/A
- EPS
- ATNI N/A
- VOR N/A
- Revenue
- ATNI $724,308,000.00
- VOR N/A
- Revenue This Year
- ATNI $1.57
- VOR N/A
- Revenue Next Year
- ATNI $2.09
- VOR N/A
- P/E Ratio
- ATNI N/A
- VOR N/A
- Revenue Growth
- ATNI N/A
- VOR N/A
- 52 Week Low
- ATNI $13.76
- VOR $2.62
- 52 Week High
- ATNI $23.60
- VOR $65.80
- Technical
- Relative Strength Index (RSI)
- ATNI 80.69
- VOR 20.61
- Support Level
- ATNI $14.16
- VOR $18.39
- Resistance Level
- ATNI $19.37
- VOR $20.00
- Average True Range (ATR)
- ATNI 1.04
- VOR 1.97
- MACD
- ATNI 0.63
- VOR -1.66
- Stochastic Oscillator
- ATNI 100.00
- VOR 4.63
About ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.